Last reviewed · How we verify
NCT07292207: ARCHE
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
Phase 2 trial testing Abemaciclib 150 MG Oral Tablet in ctDNA Monitoring in 30 participants. Not yet recruiting.
30 November 2028
Quick facts
| Lead sponsor | Nagoya City University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 10 January 2026 |
| Primary completion | 30 November 2028 |
| Estimated completion | 31 August 2031 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Abemaciclib 150 MG Oral Tablet — full drug profile →
Conditions studied
- ctDNA Monitoring — all drugs for ctDNA Monitoring →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Nagoya City University
Who can join
18 and older, any sex, with ctDNA Monitoring or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer after curative surgery and standard therapy. The study will also assess the safety of abemaciclib and the medical problems that may occur during treatment. Participants will receive routine follow-up after surgery, undergo regular blood tests to measure ctDNA, and, if ctDNA becomes positive, receive abemaciclib for a defined treatment period with scheduled clinic visits for examinations and safety assessments. Researchers will evaluate recurrence-free survival, distant recurrence-free survival, adverse events, the time between ctDNA positivity and clinical recurrence, and the rate of ctDNA clearance at the end of abemaciclib therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07292207
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ctDNA Monitoring
Currently open trials in the same condition.
- NCT06970912 — ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · recruiting
Other Nagoya City University trials
Trials by the same sponsor.
- NCT07164976 — Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06542484 — The Real-world Treatment Satisfaction by Gefapixiant in RCC · NA · recruiting
- NCT06535893 — Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer · Phase 2 · recruiting
- NCT06663787 — Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response b · active not recruiting
- NCT05840614 — The Remote Family Support Programs for Eating Disorders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07292207 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nagoya City University
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07292207.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing